Author + information
Galectin-3 is an emerging biomarker in heart failure (HF). Almost all data on galectin-3 have been derived from post hoc analyses from randomized clinical trials. Data from real-time populations addressing the distribution and usefulness of galectin-3 are lacking. This study was conducted to determine the clinical and biochemical correlates of galectin-3 in hospitalized class IV NYHA HF patients admited for pharmacological therapy.
Methods and Results
We included 18 HF patients, with hypertension and ischemia as main etiologies; patients were caucasian; median age 78 (mean age 73±14); 7 males (38,9%),11 females (61,1%); 11 were in sinus rhythm and 7 in atrial fibrillation; median BMI was 27, median creatinine 115 μmol/mL, median galectin-3 25.3 ng/mL. Median NT-proBNP was 10019 pg/ml. Galectin-3 was substantially elevated in all patients, positively correlated with creatinine (Spearman Coefficient of 0.54; p=0.02) but not with NTproBNP. Of our patients, concerning echocardiography data, 8 (44%) had HF with preserved (EF ≥50%) and 10 (56%) had HF with reduced EF (EF < 50%). In the group with EF ≥50%, the median LVEDV was 111 ml and in the group with EF<50% the median LVEDV was 167ml (p=0.04); in the group with EF ≥50%, the median LVESV was 48 ml and in the group with EF<50% the median LVESV was 98ml (p<0.01). Galectin-3 was equally elevated in both HFPEF or HFREF, and its correlations with creatinine, NT-proBNP, echo parameters of LV (LVEDD, LVESD, LVEF) and LA (LA diameters and volumes) were comparable in HFPEF and HFREF groups.
Galectin-3 levels are elevated in all patients with HF, and galectin-3 was positively correlated with creatinine but not with NT-proBNP. Galectin-3 was similarly elevated in HFPEF and HFREF in this contemporary HF cohort.